Two years after being introduced to the market, the FluMist intranasal vaccine appears to be safe for use among healthy people aged 5 to 49, according to the latest evidence. “It sort of confirms in a very major way the overall safety of this vaccine for the age groups for which it has been specifically used,” said Dr. Pascal James Imperato, chairman of the department of preventive medicine at State University of New York Downstate Medical Center, in New York City. “I don’t think there’s terribly much new here that we didn’t know before, but it gives an added margin of comfort.” The findings appear in the Dec. 7 issue of the Journal of the American Medical Association.
